World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
56
Citations
16138
World Ranking
14201
National Ranking
494

Gary J. Bridger publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Gary J. Bridger sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 135 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Gary J. Bridger D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Gary J. Bridger sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 56 D-Index — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Gary J. Bridger is affiliated with Liminal BioSciences in Canada, where they contribute to medical research with a focus on several specialized fields.

The primary areas of study in Bridger's work include Medicine, with significant contributions across Oncology, Hematology, and Immunology and Allergy. Their research projects also cover key topics such as Chemokine receptors and signaling, Platelet Disorders and Treatments, and Cell Adhesion Molecules Research.

Among Bridger's recent scholarly output is a 2024 publication titled A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome appearing in the journal Blood.

Frequent co-authors in Bridger's publications are:

  • Raffaele Badolato
  • Laia Alsina
  • Antoine Azar
  • Yves Bertrand
  • Audrey Anna Bolyard

In terms of publication venues, Bridger has concentrated efforts within the journal Blood, marking it as a notable platform for disseminating research findings.

The scope of Bridger's work spans investigations into molecular and cellular mechanisms underlying diseases relating to immunity and blood disorders. This includes targeted studies on receptors that mediate chemokine signaling pathways and the biological factors influencing platelet function and cell adhesion.

Best Publications

  • Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

    Hal E. Broxmeyer;Christie M. Orschell;D. Wade Clapp;Giao Hangoc

  • Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

    John F. DiPersio;Ivana N. Micallef;Patrick J. Stiff;Brian J. Bolwell

  • Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

    W. Conrad Liles;W. Conrad Liles;Hal E. Broxmeyer;Hal E. Broxmeyer;Elin Rodger;Elin Rodger;Brent Wood;Brent Wood

  • Multiple Actions of the Chemokine CXCL12 on Epithelial Tumor Cells in Human Ovarian Cancer

    Chris J. Scotton;Julia L. Wilson;Kate Scott;Gordon Stamp

  • Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

    Sigrid Hatse;Katrien Princen;Gary Bridger;Erik De Clercq

  • Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

    Craig W. Hendrix;Charles Flexner;Ronald T. MacFarland;Christen Giandomenico

  • Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

    Bruno Nervi;Pablo Ramirez;Michael P. Rettig;Geoffrey L. Uy

  • Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection

    Craig W. Hendrix;Ann C. Collier;Michael Marcel Lederman;Dominique Schols

  • AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

    Patrick Matthys;Sigrid Hatse;Kurt Vermeire;Anja Wuyts

  • Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.

    Lars Ole Gerlach;Renato T. Skerlj;Gary J. Bridger;Thue W. Schwartz

  • Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

    E De Clercq;N Yamamoto;R Pauwels;J Balzarini

  • Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)-Linked Bis-Tetraazamacrocycles That Inhibit HIV Replication. Effects of Macrocyclic Ring Size and Substituents on the Aromatic Linker

    Gary J. Bridger;Renato T. Skerlj;David Thornton;Sreenivasan Padmanabhan

  • Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.

    E De Clercq;N Yamamoto;R Pauwels;M Baba

  • AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity.

    Nicholas W. Lukacs;Aaron Berlin;Dominique Schols;Renato T. Skerlj

  • Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor: TRANSFER OF BINDING SITE TO THE CXCR3 RECEPTOR

    Mette M. Rosenkilde;Lars-Ole Gerlach;Janus S. Jakobsen;Renato T. Skerlj

  • AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates

    André Larochelle;Allen Krouse;Mark Metzger;Donald Orlic

  • Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.

    Rebecca S. Y. Wong;Veronique Bodart;Markus Metz;Jean Labrecque

  • Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.

    Gary J. Bridger;Renato T. Skerlj;Sreenivasan Padmanabhan;Stephen A. Martellucci

  • AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

    Sigrid Hatse;Katrien Princen;Erik De Clercq;Mette M. Rosenkilde

  • Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor

    Mette M. Rosenkilde;Lars Ole Gerlach;Sigrid Hatse;Renato T. Skerlj

Frequent Co-Authors

Erik De Clercq
Erik De Clercq Rega Institute for Medical Research
Thue W. Schwartz
Thue W. Schwartz University of Copenhagen
Louis M. Pelus
Louis M. Pelus Indiana University
John F. DiPersio
John F. DiPersio Washington University in St. Louis
Mette M. Rosenkilde
Mette M. Rosenkilde University of Copenhagen
David C. Dale
David C. Dale University of Washington
Giao Hangoc
Giao Hangoc Indiana University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open doors to a variety of career options in the health and science fields. Many students are now considering related online degrees that offer flexibility and diverse job prospects. For those interested in administrative roles, a popular entry point is medical billing and coding. If you’re wondering about the pros, cons, and future outlook of this path, learn more about is medical billing and coding worth it.

Health information management is another thriving field that blends biology, technology, and patient care. You can study from anywhere with a health information management online degree, making it an accessible option for busy learners.

If your interests extend to nutrition and wellness, consider pursuing an online nutrition masters. These programs focus on the science of diet, health, and metabolism, and can lead to advanced roles in healthcare or education.

For those drawn to diagnostic technology, earning an ultrasound tech certification online is a practical path. This certification prepares students for in-demand roles in hospitals and clinics, with hands-on skills that complement a biology or biochemistry background.

Best Scientists Citing Gary J. Bridger

Recently Published Articles